Treatment Options and Strategies for Antibody Mediated Rejection After Renal Transplantation

Overview

Journal Semin Immunol

Specialty Allergy & Immunology

Date 2011 Sep 24

PMID 21940179

Citations 5

Authors

Matthew H Levine

Peter L Abt

Affiliations

Soon will be listed here.

Abstract

Antibody mediated rejection is a significant clinical problem encountered in a subset of renal transplant recipients. This type of rejection has a variable pathogenesis from the presence of donor specific antibodies with no overt disease to immediate hyperacute rejection and many variations between. Antibody mediated rejection is more common in human leukocyte antigen sensitized patients. In general, transplant graft survival after antibody mediated rejection is jeopardized, with less than 50% graft survival 5 years after this diagnosis. A variety of agents have been utilized singly and in combinations to treat antibody mediated rejection with differing results and significant research efforts are being placed on developing new targets for intervention. These same agents have been used in desensitization protocols with some success. In this review, we describe the biology of antibody mediated rejection, review the available agents to treat this form of rejection, and highlight areas of ongoing and future research into this difficult clinical problem.

Citing Articles

B Cell Immunity in Lung Transplant Rejection - Effector Mechanisms and Therapeutic Implications.

Ohm B, Jungraithmayr W Front Immunol. 2022; 13:845867.

PMID: 35320934 PMC: 8934882. DOI: 10.3389/fimmu.2022.845867.

Liquid biopsies: donor-derived cell-free DNA for the detection of kidney allograft injury.

Oellerich M, Sherwood K, Keown P, Schutz E, Beck J, Stegbauer J Nat Rev Nephrol. 2021; 17(9):591-603.

PMID: 34031575 DOI: 10.1038/s41581-021-00428-0.

Clinical significance of donor-specific human leukocyte antigen antibodies in liver transplantation.

Cuadrado A, San Segundo D, Lopez-Hoyos M, Crespo J, Fabrega E World J Gastroenterol. 2015; 21(39):11016-26.

PMID: 26494958 PMC: 4607901. DOI: 10.3748/wjg.v21.i39.11016.

Effectiveness of Intravenous Immunoglobulin Plus Plasmapheresis on Antibody-mediated Rejection or Thrombotic Microangiopathy in Iranian Kidney Transplant Recipient.

Dashti-Khavidaki S, Shojaie L, Hosni A, Khatami M, Jafari A Nephrourol Mon. 2015; 7(3):e27073.

PMID: 26034746 PMC: 4450162. DOI: 10.5812/numonthly.7(3)2015.27073.

Antibody-mediated rejection in kidney transplantation: a review.

Puttarajappa C, Shapiro R, Tan H J Transplant. 2012; 2012:193724.

PMID: 22577514 PMC: 3337620. DOI: 10.1155/2012/193724.

References

Klein B, Tarte K, Jourdan M, Mathouk K, Moreaux J, Jourdan E . Survival and proliferation factors of normal and malignant plasma cells. Int J Hematol. 2003; 78(2):106-13. PMC: 2423421. DOI: 10.1007/BF02983377. View

Montgomery R, Zachary A, Racusen L, Leffell M, King K, Burdick J . Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation. 2000; 70(6):887-95. DOI: 10.1097/00007890-200009270-00006. View

Basta M, Van Goor F, Luccioli S, Billings E, Vortmeyer A, Baranyi L . F(ab)'2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins. Nat Med. 2003; 9(4):431-8. DOI: 10.1038/nm836. View

KISSMEYER-NIELSEN F, Olsen S, PETERSEN V, FJELDBORG O . Hyperacute rejection of kidney allografts, associated with pre-existing humoral antibodies against donor cells. Lancet. 1966; 2(7465):662-5. DOI: 10.1016/s0140-6736(66)92829-7. View

Becker Y, Becker B, Pirsch J, Sollinger H . Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant. 2004; 4(6):996-1001. DOI: 10.1111/j.1600-6143.2004.00454.x. View

Lefaucheur C, Loupy A, Hill G, Andrade J, Nochy D, Antoine C . Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol. 2010; 21(8):1398-406. PMC: 2938596. DOI: 10.1681/ASN.2009101065. View

Lee P, Terasaki P, Takemoto S, Lee P, Hung C, Chen Y . All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies. Transplantation. 2002; 74(8):1192-4. DOI: 10.1097/00007890-200210270-00025. View

Ciechanover A . The ubiquitin-proteasome proteolytic pathway. Cell. 1994; 79(1):13-21. DOI: 10.1016/0092-8674(94)90396-4. View

Steinmetz O, Lange-Husken F, Turner J, Vernauer A, Helmchen U, Stahl R . Rituximab removes intrarenal B cell clusters in patients with renal vascular allograft rejection. Transplantation. 2007; 84(7):842-50. DOI: 10.1097/01.tp.0000282786.58754.2b. View

10.

Einecke G, Sis B, Reeve J, Mengel M, Campbell P, Hidalgo L . Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant. 2009; 9(11):2520-31. DOI: 10.1111/j.1600-6143.2009.02799.x. View

11.

Mauiyyedi S, Colvin R . Humoral rejection in kidney transplantation: new concepts in diagnosis and treatment. Curr Opin Nephrol Hypertens. 2002; 11(6):609-18. DOI: 10.1097/00041552-200211000-00007. View

12.

Jordan S, Quartel A, Czer L, Admon D, Chen G, Fishbein M . Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action. Transplantation. 1998; 66(6):800-5. DOI: 10.1097/00007890-199809270-00017. View

13.

Jordan S, Cunningham-Rundles C, McEwan R . Utility of intravenous immune globulin in kidney transplantation: efficacy, safety, and cost implications. Am J Transplant. 2003; 3(6):653-64. DOI: 10.1034/j.1600-6143.2003.00121.x. View

14.

Sberro-Soussan R, Zuber J, Suberbielle-Boissel C, Candon S, Martinez F, Snanoudj R . Bortezomib as the sole post-renal transplantation desensitization agent does not decrease donor-specific anti-HLA antibodies. Am J Transplant. 2010; 10(3):681-6. DOI: 10.1111/j.1600-6143.2009.02968.x. View

15.

Williams G, HUME D, Hudson Jr R, Morris P, Kano K, Milgrom F . "Hyperacute" renal-homograft rejection in man. N Engl J Med. 1968; 279(12):611-8. DOI: 10.1056/NEJM196809192791201. View

16.

Vo A, Lukovsky M, Toyoda M, Wang J, Reinsmoen N, Lai C . Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med. 2008; 359(3):242-51. DOI: 10.1056/NEJMoa0707894. View

17.

Schweitzer E, Wilson J, Fernandez-Vina M, Fox M, Gutierrez M, Wiland A . A high panel-reactive antibody rescue protocol for cross-match-positive live donor kidney transplants. Transplantation. 2000; 70(10):1531-6. DOI: 10.1097/00007890-200011270-00023. View

18.

Pagano M, Tam S, Theodoras A, Del Sal G, Chau V, Yew P . Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science. 1995; 269(5224):682-5. DOI: 10.1126/science.7624798. View

19.

Lucas J, Co J, Nwaogwugwu U, Dosani I, Sureshkumar K . Antibody-mediated rejection in kidney transplantation: an update. Expert Opin Pharmacother. 2011; 12(4):579-92. DOI: 10.1517/14656566.2011.525219. View

20.

Jordan S, Reinsmoen N, Peng A, Lai C, Cao K, Villicana R . Advances in diagnosing and managing antibody-mediated rejection. Pediatr Nephrol. 2010; 25(10):2035-45. PMC: 2923704. DOI: 10.1007/s00467-009-1386-4. View